220141-23-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-fluoro-2-(trifluoromethyl)benzoate is used as an intermediate in the synthesis of various pharmaceutical compounds for its unique chemical properties that can enhance the activity and efficacy of the final drug products.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 4-fluoro-2-(trifluoromethyl)benzoate serves as a key component in the development of pesticides and other agrochemicals, leveraging its chemical structure to improve the performance and selectivity of these products.
Used in Organic Compounds Synthesis:
Methyl 4-fluoro-2-(trifluoromethyl)benzoate is utilized as a building block in the synthesis of a wide range of organic compounds, contributing to the creation of new materials with specific properties for various applications.
It is crucial to handle Methyl 4-fluoro-2-(trifluoromethyl)benzoate with care and adhere to proper safety protocols during its use in any application due to its chemical nature.

Upstream product

• 79-37-8 oxalyl dichloride 
• 141179-72-8 4-fluoro-2-trifluoromethylbenzoic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 220462-00-0 4-(3-Methyl-1H-pyrazol-1-yl)-2-(trifluoromethyl)-benzoic acid methyl ester 
• 790695-28-2 methyl 4-[methyl(propyl)amino]-2-(trifluoromethyl)benzoate 
• 530091-65-7 (R)-methyl 4-(3-methylpyrrolidin-1-yl)-2-(trifluoromethyl)benzoate 
• 1228581-92-7 methyl 4-(phenyloxy)-2-(trifluoromethyl)benzoate 
• 948832-87-9 4-[(2-{[1-(3,4-dichlorobenzyl)piperidin-4-yl]amino}-2-oxoethyl)thio]-2-(trifluoromethyl)benzoic acid 
• 1228581-40-5 [4-piperidin-1-yl-2-(trifluoromethyl)phenyl]methanol 
• 1228581-19-8 methyl 4-piperidin-1-yl-2-(trifluoromethyl)benzoate 
• 1262328-75-5 4-(4-formyl-2-methoxyphenoxy)-2-trifluoromethylbenzoic acid methyl ester 
• 873927-78-7 4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy]-2-trifluoromethylbenzoic acid methyl ester 
• 1262328-59-5 4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxyphenoxy]-2-trifluoromethylbenzoic acid methyl ester 
• 220602-65-3 [4-(3-methyl-1H-pyrazol-1-yl)-2-(trifluoromethyl)-phenyl]-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 
• 220462-01-1 4-(3-Methyl-1H-pyrazol-1-yl)-2-(trifluoromethyl)-benzoic acid 
• 1012869-23-6 4-Dimethylamino-2-trifluoromethyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF

[Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease ind

N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

TRICYCLIC VASOPRESSIN AGONISTS

The present invention provides compounds of general formula (I): wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilising these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.

TRICYCLIC PYRIDINE N-OXIDES VASOPRESSIN AGONISTS

The present invention provides compounds of general formula (I) as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes, insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.

Tricyclic pyrido vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

Tricyclic pyridine N-oxides vasopressin agonists

The present invention provides compounds of the general formula: as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.

Tricyclic vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.